We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    avid100 | Recruiting Studies
Previous Study | Return to List | Next Study

AVID100 in Advanced Epithelial Carcinomas

This study is currently recruiting participants.
Verified May 2017 by Formation Biologics
Sponsor:
ClinicalTrials.gov Identifier:
NCT03094169
First Posted: March 29, 2017
Last Update Posted: May 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Formation Biologics
  Purpose
Approximately 80 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100.

Condition Intervention Phase
Solid Tumor, Adult Drug: AVID100 IV Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:
Uncontrolled, open label, non-randomized, Enrollment in the order of confirmation of eligibility, Escalating doses of study drug in sequential patient cohorts (Phase 1a).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin

Further study details as provided by Formation Biologics:

Primary Outcome Measures:
  • Determine safety and tolerability of AVID100 [ Time Frame: 6 months ]
    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment


Secondary Outcome Measures:
  • PK Profile of Total Antibody [ Time Frame: 9 months ]
    Characterization of the pharmacokinetic profile of total antibody

  • Evaluation of the preliminary anti-neoplastic effects of AVID100 [ Time Frame: 9 months ]
    Number of Participants with evidence of objective response or stable disease and duration of response


Estimated Enrollment: 30
Actual Study Start Date: February 1, 2017
Estimated Study Completion Date: August 1, 2019
Estimated Primary Completion Date: April 1, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dose escalation
Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
Drug: AVID100 IV
AVID100 is administered once every 3 weeks

Detailed Description:

On Day 1 of study, patients will receive study drug administered by 1-hour IV infusion in a fixed 100 mL volume. AVID100 will be administered once every 3 weeks (Q3W) with administration on Day 1 of the first week, followed by a 3-week recovery period.

Evidence of progressive disease at any point in the study will necessitate withdrawal of the patient from further participation so that alternative management of their malignancy may be considered.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Phase 1):

  1. Patients with a documented (histologically- or cytologically-proven) solid tumor epithelial carcinoma that is locally advanced or metastatic
  2. Patients with a malignancy that is either refractory to standard therapy, or for which no standard therapy is available
  3. Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor
  4. Phase 1a Dose-Escalation Cohorts: Patients with measurable or non-measurable disease according to RECIST, v1.1 criteria. To include patients reasonably likely to express EGFR.

Patients to be Excluded (patients must not meet any of the following criteria Phase 1 only)

  1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a medically effective method of contraception.
  2. Patients with known central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
  3. Patients with a malignancy other than that of epithelial origin
  4. Patients with hematologic abnormalities at baseline
  5. Patients with a significant cardiovascular disease or condition
  6. Patients with a significant ocular disease or condition
  7. Patients with a significant pulmonary disease or condition
  8. History of pneumonia within 6 months prior to the first study drug administration
  9. Patients with significant gastrointestinal (GI) abnormalities
  10. Patients with non-healing wounds on any part of the body

Drugs and Other Treatments to be Excluded

  1. Any antineoplastic agent for the primary malignancy (standard or investigational), without delayed toxicity, within 4 weeks, 5 plasma half-lives, or twice the duration of the biological effect, whichever is shortest, prior to first study drug administration and during study with the exception of: Nitrosoureas and nitrogen mustard within 6 weeks prior to first study drug administration and during study
  2. Any other investigational treatments during study. This includes participation in any medical device or other therapeutic intervention clinical trials.
  3. Radiotherapy for target lesions within 4 weeks prior to first study drug administration and during study
  4. Herbal preparations or related over-the-counter (OTC) preparations/supplements containing herbal ingredients aimed at treating the underlying malignancy within 2 weeks prior to first study drug administration and during study
  5. Strong inhibitors and/or inducers of cytochrome P450 (CYP) isoenzyme 3A4 within 2 weeks prior to first study drug administration and during study
  6. Immunosuppressive or systemic hormonal therapy within 2 weeks prior to first study drug administration and during study.
  7. Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study; thereafter prophylactic use of growth factors is allowed as clinically indicated
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03094169


Contacts
Contact: Sandra Sinclair, MHA/ED, RN 832-622-1699 sandra@formationbiologics.com

Locations
United States, Texas
South Texas Accelerated Research Therapeutics Recruiting
San Antonio, Texas, United States, 78229
Contact: Isabel Jimenez, MSN, RN    210-593-5252    isabel.jimenez@start.stoh.com   
Sub-Investigator: Anthony W Tolcher, MD         
Sub-Investigator: Muralidhar Beeram, MD         
Principal Investigator: Kyriakos Papadopoulos, MD         
Sub-Investigator: Amita Patnaik, MD         
Sub-Investigator: Drew W Rasco, MD         
Sub-Investigator: Lon S Smith, MD         
Sponsors and Collaborators
Formation Biologics
Investigators
Principal Investigator: Kyriakos W Popadopoulos, MD Phase 1 Principal Investigator
  More Information

Responsible Party: Formation Biologics
ClinicalTrials.gov Identifier: NCT03094169     History of Changes
Other Study ID Numbers: AVID100-01
First Submitted: February 6, 2017
First Posted: March 29, 2017
Last Update Posted: May 19, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No